SUBSCRIBE
SUBSCRIBE

SpringWorks Therapeutics

NEWS
Business
R&D Cooperation Between China and Western Pharma Companies Up 70 Percent
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
September 14, 2018
 · 
3 min read
 · 
Alex Keown
Business
Movers and Shakers for Sept. 10
Let’s take a look at who made a splash in the pharma and biotech world the past week.
September 7, 2018
 · 
5 min read
 · 
Alex Keown
Business
China’s Beigene Teams up With Springworks to Target Advanced Solid Tumors
SpringWorks Therapeutics and BeiGene, Ltd. have teamed up to develop therapeutics that will target advanced solid tumors that contain RAS mutations, as well as other MAPK aberrations.
September 6, 2018
 · 
3 min read
 · 
Alex Keown
Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million
Business
Pfizer Spins Off 4 of Its Best Drug Candidates Into a Startup With $103 Million
September 25, 2017
 · 
2 min read
Load More
AWARDS
  • NextGen Class of 2019
JOBS
IN THE PRESS
Business
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 2, 2023
 · 
14 min read
Policy
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDAFDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023
June 5, 2023
 · 
10 min read
Drug Development
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
May 30, 2023
 · 
10 min read
Drug Development
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
May 25, 2023
 · 
16 min read
Pharm Country
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
May 11, 2023
 · 
13 min read
Business
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 3, 2023
 · 
13 min read
SpringWorks & BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
 · 
12 min read
Biotech Bay
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
 · 
12 min read
Biotech Bay
BeiGene & SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
 · 
12 min read
Genetown
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
April 17, 2023
 · 
12 min read
Load More